EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Original and generic medicines: clinical, economic and social aspects in the context of health care systems

Marcin Lewandowski, Urszula Religioni, Barańska Agnieszka, Wdowiak Krystian, Adam Kobayashi, Mariola Borowska, Czech Marcin, Wierzbiński Piotr, Śliż Daniel, Plagens–Rotman Katarzyna, Piotr Merks

Pharmacy Reports · 2025

DOI: 10.51511/pr.105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Reports, 2025. Verfasst von Marcin Lewandowski und 10 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This narrative review synthesizes evidence on clinical, regulatory, economic, and social aspects of generic drug use, focusing on European and Polish contexts. We searched MEDLINE/PubMed, Embase, Scopus, Web of Science, Cochrane Library, and regulatory sources for English and Polish-language records published January 2015 to October 2025. Regulatory authorities apply rigorous bioequivalence and Good Manufacturing Practice standards ensuring generics meet the same quality requirements as branded counterparts. Across most small-molecule indications, these standards predict comparable therapeutic outcomes, with residual caution for narrow-therapeutic-index or modified-release medicines. Despite regulatory assurance, perceptions of inferiority persist among healthcare professionals and patients, influenced by misinformation, inconsistent communication, and branding cues. Economically, generics consistently reduce public and out-of-pocket expenditures and enable reinvestment in innovative therapies. Policy tools such as reference pricing, INN prescribing, and pharmacist substitution shape uptake, though implementation varies. Supply-chain vulnerabilities and market-sustainability pressures threaten continuity of access. Four priority actions emerge: improve transparency of regulatory decisions and product-level information at point of care, standardize professional and public education on generic equivalence, protect sustainable competition through calibrated pricing and diversified sourcing, and prioritize real-world comparative research in sensitive indications. These measures would strengthen trust, ensure reliable access, and allow savings to be reinvested in high-value innovation.

Zitieren

APA

Lewandowski, M., Religioni, U., Agnieszka, B., Krystian, W., Kobayashi, A., Borowska, M., Marcin, C., Piotr, W., Daniel, Ś., Katarzyna, P., & Merks, P. (2025). Original and generic medicines: clinical, economic and social aspects in the context of health care systems. Pharmacy Reports. https://doi.org/10.51511/pr.105

Vancouver

Lewandowski M, Religioni U, Agnieszka B, Krystian W, Kobayashi A, Borowska M, et al. Original and generic medicines: clinical, economic and social aspects in the context of health care systems. Pharmacy Reports. 2025. doi:10.51511/pr.105

BibTeX
@article{Lewandowski2025,
  author = {Lewandowski, Marcin and Religioni, Urszula and Agnieszka, Barańska and Krystian, Wdowiak and Kobayashi, Adam and Borowska, Mariola and Marcin, Czech and Piotr, Wierzbiński and Daniel, Śliż and Katarzyna, Plagens–Rotman and Merks, Piotr},
  title = {Original and generic medicines: clinical, economic and social aspects in the context of health care systems},
  journal = {Pharmacy Reports},
  year = {2025},
  doi = {10.51511/pr.105}
}
Kostenlos starten →